Trial Profile
Investigation of the immune infiltrate of metastatic melanoma under immune checkpoint inhibition
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Oct 2017 New trial record
- 09 Sep 2017 Results presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference